NYSEAMERICAN:CVM Cel-Sci Q4 2025 Earnings Report $1.04 -0.04 (-3.70%) Closing price 06/30/2026 04:10 PM EasternExtended Trading$1.07 +0.03 (+2.50%) As of 06/30/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings History Cel-Sci EPS ResultsActual EPS-$0.76Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACel-Sci Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACel-Sci Announcement DetailsQuarterQ4 2025Date12/23/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Cel-Sci Earnings HeadlinesCel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest UpdateJune 30 at 4:40 AM | americanbankingnews.comCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer CareJune 24, 2026 | businesswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Cel-Sci (NYSEAMERICAN:CVM) Stock Price Up 1% - Time to Buy?June 24, 2026 | americanbankingnews.comCEL-SCI Announces Closing of OfferingJune 16, 2026 | businesswire.comCEL-SCI slides after pricing $2.5M best-efforts common stock offering at $1.00/shareJune 15, 2026 | msn.comSee More Cel-Sci Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cel-Sci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cel-Sci and other key companies, straight to your email. Email Address About Cel-SciCel-Sci (NYSEAMERICAN:CVM) is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates. The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells. Multikine has been evaluated in a pivotal Phase III clinical trial, and CEL-SCI has conducted additional clinical studies and manufacturing development to support potential registration in the United States and abroad. Beyond Multikine, the company is advancing early-stage programs in infectious disease and oncology that leverage its expertise in immune modulation. CEL-SCI has carried out clinical trials and manufacturing activities in multiple regions, including North America, Europe, Latin America and South Africa. Its research and development operations encompass in-house laboratories in Virginia and collaborations with contract research organizations around the world. This global footprint reflects the company’s commitment to rigorous clinical testing and regulatory engagement in key markets. Under the leadership of President and Chief Executive Officer Geert Kersten, CEL-SCI maintains a small executive team supported by a board of directors with expertise in biotechnology, clinical operations and regulatory affairs. The company’s scientific staff comprises immunologists, process development specialists and clinical trial managers who collectively steer CEL-SCI’s programs from preclinical research through late-stage development. View Cel-Sci ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Wall Street Still Sees Massive Upside for AeroVironment StockManchester United’s Stock Rally Faces a Test Beyond Old TraffordBest Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs ProofPalantir’s Rough 2026 Start Raises a Bigger Question About Its AI MoatWinnebago Misses Estimates, But Surges 14% After EarningsBlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneTrip.com’s Selloff Raises a Bigger Question About Its Travel Recovery Story Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
